Skip to main content
PMC home page
Sarcoma logoLink to Sarcoma
. 1998 Jun;2(2):97–105. doi: 10.1080/13577149878055

Long-Term Neurotoxicity of Chemotherapy in Adolescents and Young Adults Treated for Bone and Soft Tissue Sarcomas

Helena M Earl 1,✉, Sean Connolly 2, Christos Latoufis 3, Karen Eagle 3, Catherine M Ash 3, Clare Fowler 2, Robert L Souhami 3
PMCID: PMC2395382  PMID: 18521240

Abstract

Purpose. To study the long-term neurotoxicity of chemotherapy in adolescents and young adults treated for bone and soft tissue sarcomas.

Patients and Methods. Thirty-six adolescents and young adults (median age 17 years) were examined following chemotherapy for bone and soft tissue sarcomas. Twenty-nine (29/36) had received cisplatin (median 400 mg/m2), 15/36 ifosfamide (median 20 g/m2), and 12/36 vincristine (median 16 mg). Neurotoxicity was assessed at a median of 8 months (range, 1–54 months) after completion of chemotherapy by clinical examination, nerve conduction studies, audiograms and autonomic function tests. The same nerve conduction studies were carried out in 20 normal volunteers to define normal ranges in this age group.

Results. Sixteen patients (44%) had a significant reduction in deep tendon reflexes, and this clinical parameter correlated well with abnormalities detected in nerve conduction studies. Vibration perception threshold (VPT) was raised in 20/36 patients (55%) and this was the most sensitive single test in the assessment of neuropathy. There was a significant correlation between VPT and cumulative cisplatin dose received in mg/m-2 (r=0.607, p<0.01). Ten of 29 patients (35%) had abnormal nerve conduction studies with a pattern characteristic of sensory axonal neuropathy. No patient complained of auditory symptoms, but minor high tone hearing loss was detected by audiograms in 5/28 patients who had received cisplatin. No patients had symptoms of autonomic neuropathy, but autonomic function tests showed minor abnormalities in 4/22 patients tested, and all had received cisplatin.

Conclusions. This study demonstrates significant, although asymptomatic, long-term neurotoxicity of cisplatin in adolescents and young adults receiving chemotherapy for bone and soft tissue sarcomas. Follow-up studies are planned to assess whether these neurological deficits improve with time.

Full Text

The Full Text of this article is available as a PDF (170.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apfel S. C., Arezzo J. C., Lipson L., Kessler J. A. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol. 1992 Jan;31(1):76–80. doi: 10.1002/ana.410310114. [DOI] [PubMed] [Google Scholar]
  2. Ashraf M., Riggs J. E., Wearden S., Scotchel P. Prospective study of nerve conduction parameters and serum magnesium following cisplatin therapy. Gynecol Oncol. 1990 Apr;37(1):29–33. doi: 10.1016/0090-8258(90)90302-2. [DOI] [PubMed] [Google Scholar]
  3. Boogerd W., ten Bokkel Huinink W. W., Dalesio O., Hoppenbrouwers W. J., van der Sande J. J. Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. J Neurooncol. 1990 Dec;9(3):255–263. doi: 10.1007/BF02341156. [DOI] [PubMed] [Google Scholar]
  4. Boyer M., Raghavan D., Harris P. J., Lietch J., Bleasel A., Walsh J. C., Anderson S., Tsang C. S. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol. 1990 Jan;8(1):21–26. doi: 10.1200/JCO.1990.8.1.21. [DOI] [PubMed] [Google Scholar]
  5. Cavaletti G., Petruccioli M. G., Tredici G., Marmiroli P., Barajon I., Fabbrica D., Di Francesco A. Effects of repeated administration of low doses of cisplatin on the rat nervous system. Int J Tissue React. 1991;13(3):151–157. [PubMed] [Google Scholar]
  6. Cavanagh J. B. Sensorimotor neuropathy and cisplatin and adriamycin toxicity. J Neurol Neurosurg Psychiatry. 1986 Aug;49(8):964–965. doi: 10.1136/jnnp.49.8.964-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cersosimo R. J. Cisplatin neurotoxicity. Cancer Treat Rev. 1989 Dec;16(4):195–211. doi: 10.1016/0305-7372(89)90041-8. [DOI] [PubMed] [Google Scholar]
  8. Cowan J. D., Kies M. S., Roth J. L., Joyce R. P. Nerve conduction studies in patients treated with cis-diamminedichloroplatinum(II): a preliminary report. Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1119–1122. [PubMed] [Google Scholar]
  9. Daugaard G. K., Petrera J., Trojaborg W. Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin. Acta Neurol Scand. 1987 Aug;76(2):86–93. doi: 10.1111/j.1600-0404.1987.tb03551.x. [DOI] [PubMed] [Google Scholar]
  10. Dewar J., Lunt H., Abernethy D. A., Dady P., Haas L. F. Cisplatin neuropathy with Lhermitte's sign. J Neurol Neurosurg Psychiatry. 1986 Jan;49(1):96–99. doi: 10.1136/jnnp.49.1.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Earl H. M., Pringle J., Kemp H., Morittu L., Miles D., Souhami R. Chemotherapy of malignant fibrous histiocytoma of bone. Ann Oncol. 1993 May;4(5):409–415. doi: 10.1093/oxfordjournals.annonc.a058521. [DOI] [PubMed] [Google Scholar]
  12. Elderson A., Gerritsen van der Hoop R., Haanstra W., Neijt J. P., Gispen W. H., Jennekens F. G. Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. J Neurol Sci. 1989 Nov;93(2-3):167–174. doi: 10.1016/0022-510x(89)90187-1. [DOI] [PubMed] [Google Scholar]
  13. Ewing D. J., Clarke B. F. Autonomic neuropathy: its diagnosis and prognosis. Clin Endocrinol Metab. 1986 Nov;15(4):855–888. doi: 10.1016/s0300-595x(86)80078-0. [DOI] [PubMed] [Google Scholar]
  14. Fosså S. D., Aass N., Ous S., Waehre H. Long-term morbidity and quality of life in testicular cancer patients. Scand J Urol Nephrol Suppl. 1991;138:241–246. [PubMed] [Google Scholar]
  15. Fowler C. J., Carroll M. B., Burns D., Howe N., Robinson K. A portable system for measuring cutaneous thresholds for warming and cooling. J Neurol Neurosurg Psychiatry. 1987 Sep;50(9):1211–1215. doi: 10.1136/jnnp.50.9.1211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gregg R. W., Molepo J. M., Monpetit V. J., Mikael N. Z., Redmond D., Gadia M., Stewart D. J. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol. 1992 May;10(5):795–803. doi: 10.1200/JCO.1992.10.5.795. [DOI] [PubMed] [Google Scholar]
  17. Grunberg S. M., Sonka S., Stevenson L. L., Muggia F. M. Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol. 1989;25(1):62–64. doi: 10.1007/BF00694340. [DOI] [PubMed] [Google Scholar]
  18. Hainsworth J. D., Burnett L. S., Jones H. W., 3rd, Grosh W. W., Johnson D. H., Greco F. A. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma. J Clin Oncol. 1990 Mar;8(3):502–508. doi: 10.1200/JCO.1990.8.3.502. [DOI] [PubMed] [Google Scholar]
  19. Hamers F. P., van der Hoop R. G., Steerenburg P. A., Neijt J. P., Gispen W. H. Putative neurotrophic factors in the protection of cisplatin-induced peripheral neuropathy in rats. Toxicol Appl Pharmacol. 1991 Dec;111(3):514–522. doi: 10.1016/0041-008x(91)90255-d. [DOI] [PubMed] [Google Scholar]
  20. Hansen S. W. Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer. BMJ. 1990 Feb 24;300(6723):511–512. doi: 10.1136/bmj.300.6723.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hansen S. W., Helweg-Larsen S., Trojaborg W. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol. 1989 Oct;7(10):1457–1461. doi: 10.1200/JCO.1989.7.10.1457. [DOI] [PubMed] [Google Scholar]
  22. Heier M. S., Nilsen T., Graver V., Aass N., Fosså S. D. Raynaud's phenomenon after combination chemotherapy of testicular cancer, measured by laser Doppler flowmetry. A pilot study. Br J Cancer. 1991 Apr;63(4):550–552. doi: 10.1038/bjc.1991.129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. List A. F., Kummet T. D. Spinal cord toxicity complicating treatment with cisplatin and etoposide. Am J Clin Oncol. 1990 Jun;13(3):256–258. doi: 10.1097/00000421-199006000-00016. [DOI] [PubMed] [Google Scholar]
  24. Mollman J. E. Cisplatin neurotoxicity. N Engl J Med. 1990 Jan 11;322(2):126–127. doi: 10.1056/NEJM199001113220210. [DOI] [PubMed] [Google Scholar]
  25. Mollman J. E., Glover D. J., Hogan W. M., Furman R. E. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer. 1988 Jun 1;61(11):2192–2195. doi: 10.1002/1097-0142(19880601)61:11<2192::aid-cncr2820611110>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  26. Müller L. J., Gerritsen van der Hoop R., Moorer-van Delft C. M., Gispen W. H., Roubos E. W. Morphological and electrophysiological study of the effects of cisplatin and ORG.2766 on rat spinal ganglion neurons. Cancer Res. 1990 Apr 15;50(8):2437–2442. [PubMed] [Google Scholar]
  27. Nielsen V. K. The peripheral nerve function in chronic renal failure. IV. An analysis of the vibratory perception threshold. Acta Med Scand. 1972 Apr;191(4):287–296. [PubMed] [Google Scholar]
  28. Pagès M., Pagès A. M., Bories-Azeau L. Severe sensorimotor neuropathy after cisplatin therapy. J Neurol Neurosurg Psychiatry. 1986 Mar;49(3):333–334. doi: 10.1136/jnnp.49.3.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Raivich G., Kreutzberg G. W. Nerve growth factor and regeneration of peripheral nervous system. Clin Neurol Neurosurg. 1993;95 (Suppl):S84–S88. doi: 10.1016/0303-8467(93)90041-e. [DOI] [PubMed] [Google Scholar]
  30. Robinson L. R., Temkin N. R., Fujimoto W. Y., Stolov W. C. Effect of statistical methodology on normal limits in nerve conduction studies. Muscle Nerve. 1991 Nov;14(11):1084–1090. doi: 10.1002/mus.880141108. [DOI] [PubMed] [Google Scholar]
  31. Rosen G., Marcove R. C., Huvos A. G., Caparros B. I., Lane J. M., Nirenberg A., Cacavio A., Groshen S. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106 (Suppl):55–67. doi: 10.1007/BF00625054. [DOI] [PubMed] [Google Scholar]
  32. Rosen G. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics. 1985 May;8(5):659–664. doi: 10.3928/0147-7447-19850501-19. [DOI] [PubMed] [Google Scholar]
  33. Samuels B. L., Vogelzang N. J., Kennedy B. J. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol. 1987;19(3):253–256. doi: 10.1007/BF00252982. [DOI] [PubMed] [Google Scholar]
  34. Sebille A., St-Guily J. L., Angelard B., de Stabenrath A. Low prevalence of cisplatin-induced neuropathy after 4-day continuous infusion in head and neck cancer. Cancer. 1990 Jun 15;65(12):2644–2647. doi: 10.1002/1097-0142(19900615)65:12<2644::aid-cncr2820651208>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  35. Siegal T., Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer. 1990 Sep 15;66(6):1117–1123. doi: 10.1002/1097-0142(19900915)66:6<1117::aid-cncr2820660607>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  36. Stiller C. A., Bunch K. J. Trends in survival for childhood cancer in Britain diagnosed 1971-85. Br J Cancer. 1990 Nov;62(5):806–815. doi: 10.1038/bjc.1990.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Thompson S. W., Davis L. E., Kornfeld M., Hilgers R. D., Standefer J. C. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer. 1984 Oct 1;54(7):1269–1275. doi: 10.1002/1097-0142(19841001)54:7<1269::aid-cncr2820540707>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  38. Tomiwa K., Nolan C., Cavanagh J. B. The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol. 1986;69(3-4):295–308. doi: 10.1007/BF00688308. [DOI] [PubMed] [Google Scholar]
  39. Walsh T. J., Clark A. W., Parhad I. M., Green W. R. Neurotoxic effects of cisplatin therapy. Arch Neurol. 1982 Nov;39(11):719–720. doi: 10.1001/archneur.1982.00510230045013. [DOI] [PubMed] [Google Scholar]
  40. van der Hoop R. G., Vecht C. J., van der Burg M. E., Elderson A., Boogerd W., Heimans J. J., Vries E. P., van Houwelingen J. C., Jennekens F. G., Gispen W. H. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med. 1990 Jan 11;322(2):89–94. doi: 10.1056/NEJM199001113220204. [DOI] [PubMed] [Google Scholar]
  41. van der Hoop R. G., van der Burg M. E., ten Bokkel Huinink W. W., van Houwelingen C., Neijt J. P. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer. 1990 Oct 15;66(8):1697–1702. doi: 10.1002/1097-0142(19901015)66:8<1697::aid-cncr2820660808>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]

Articles from Sarcoma are provided here courtesy of Wiley

RESOURCES